by Romain Magnez | Jul 30, 2024 | News
Vaxinano presents latest vaccine research and development activities to the Animal Health, Nutrition and Technology Innovation Europe 2024, 4-6 March in London. Visit and meet the team to partner with Vaxinano, the nasal and mucosal vaccine company ! #toxoplasmosis...
by Romain Magnez | Jul 30, 2024 | News
Ocular Toxoplasmosis is a public health problem across south america. In Colombia, 6% of the population in Quindio department have retinal scarring infection. This parasite can continue to destroy the retina over time, even after the acute phase of the infection has...
by Romain Magnez | Jul 30, 2024 | News
We are thrilled to announce that the Mexican government has granted approval for the importation and use of our Toxoplasmosis Vaccine in support of endangered animals hosted in Mexican zoos. This marks the 10th country where our vaccine is now benefiting primates. We...
by Romain Magnez | Feb 9, 2024 | Publications
Title : Maltodextrin-Nanoparticles as a Delivery System for Nasal Vaccines: A Review Article Abstract: Nanoparticles are increasingly being studied as antigen delivery systems for immunization with nasal vaccines. The addition of adjuvants is still generally required...
by Romain Magnez | Dec 9, 2023 | Publications
Title: Nasal vaccination of six squirrel monkeys (Saimiri sciureus): Improved immunization protocol against Toxoplasma gondii with a nanoparticle-born vaccine. Fasquelle et al. 2023 International Journal for Parasitology: Parasites and Wildlife Abstract: Toxoplasma...
